INSUBCONTINENT EXCLUSIVE:
million to private equity firm Unison, as the seller expects fewer future incentives from Tokyo for generic drugs would make the business
less attractive.
ET was the first to report this sale by the company in its edition dated November 1
?1,129 crore, compared with ?4,362 crore as on September 30
taking away the incentives which were given for generics
markets and strategic priorities to achieve sustainable growth
portfolio will continue, including in Japan, according to Nilesh Gupta.
Lupin had acquired Kyowa in 2007 from the Sugiura family, and was
the first Indian company to have entered the complex Japanese drug market.